Literature DB >> 35711497

Diagnostic Value of Multislice Spiral Computed Tomography Combined with Serum AFP, TSGF, and GP73 Assay in the Diagnosis of Primary Liver Cancer.

Chuanwen Yu1, Chuang Sun1.   

Abstract

Objective: To explore the diagnostic value of multislice spiral computed tomography (MSCT) scan combined with serum alpha-fetoprotein (AFP), tumor-specific growth factor (TSGF), and Golgi protein73 (GP73) assays in the diagnosis of primary liver cancer (PLC).
Methods: Totally, 60 patients with PLC admitted to The Second Hospital of Dalian Medical University from January 2019 to January 2020 were included in group A, 60 patients with liver cirrhosis were included in group B, and 60 healthy subjects were included in group C. The serum AFP, TSGF, and GP73 levels were determined, and all participants received MSCT scanning. The diagnostic efficacy of MSCT, assays of serum AFP, TSGF, and GP73, and their combined detection was analyzed.
Results: Group A had the highest levels of AFP, TSGF, and GP73, followed by group B, and then group C. The sensitivity, specificity, positive predictive value, and negative predictive value of MSCT for PLC were 80.0%,91.7%, 82.8%, and 90.2%, respectively, while those of combined detection of MSCT plus serum AFP, TSGF, and GP73 for PLC were 100.0%, 93.3%, 88.2%, and 100.0%. The combined detection was associated with significantly a higher detection rate of PLC versus stand-alone detection.
Conclusion: MSCT plus serum AFP, TSGF, and GP73 has a higher detection rate versus stand-alone detection, which shows great potential in the diagnosis of PLC.
Copyright © 2022 Chuanwen Yu and Chuang Sun.

Entities:  

Year:  2022        PMID: 35711497      PMCID: PMC9197641          DOI: 10.1155/2022/6581127

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.650


1. Introduction

The incidence of primary liver cancer (PLC) accounts for more than 50% of the total prevalence of liver cancer. The early stage of PLC is mostly asymptomatic, and the disease may have progressed to an advanced stage by the time of diagnosis where surgical outcomes are unfavorable [1, 2]. Thus, early diagnosis is crucial for the improvement of the prognosis of patients [3]. At present, diagnosis of PLC is mostly achieved by imaging examination, and multislice spiral computed tomography (MSCT) can clearly display the liver conditions, which is of high clinical application value [4, 5]. It was found that the detection rate of contrast-enhanced CT scans was about 80.0%, but its diagnostic efficiency might be compromised in the detection of small tumors, which requires additional diagnostic means to enhance the diagnostic accuracy [6, 7]. Tumor markers such as alpha-fetoprotein (AFP), tumor-specific growth factor (TSGF), and Golgi protein 73 (GP73) are commonly used for tumor diagnosis. AFP is commonly used for PLC diagnosis but is associated with poor sensitivity and specificity. Recent research has shown that the combined assay of AFP with other tumor markers might potentiate the diagnostic efficiency [8]. TSGF is a polypeptide secreted during the production and proliferation of malignant tumors, and its secretion mechanism is irrelevant to liver injuries caused by benign liver diseases such as liver cysts and cirrhosis [9]. Therefore, the determination of serum TSGF may facilitate the differentiation between PLC and liver cirrhosis. GP73 is a transmembrane protein of the Golgi apparatus and is rarely detected in the liver cells of healthy people. The elevation of its expression indicates cancerous changes of liver cells [10]. The serum levels of GP73 increase with the severity of liver inflammatory responses, but not significantly. The combination of AFP, TSGF, and GP73 contributes to a higher diagnostic efficiency for PLC [11]. Accordingly, this study was conducted to explore the diagnostic value of MSCT plus serum AFP, TSGF, and GP73 levels in PLC.

2. Materials and Methods

2.1. General Materials

Totally 60 patients with PLC admitted to The Second Hospital of Dalian Medical University from January 2019 to January 2020 were included in group A, 60 patients with liver cirrhosis were included in group B, and 60 healthy subjects were included in group C. There were no significant differences between the three groups in terms of baseline characteristics (P > 0.05), as shown in Table 1.
Table 1

Comparison of baseline characteristics.

GroupGroup A (n = 60)Group B (n = 60)Group C (n = 60) P value
Gender (male/female)35/2534/2633/27>0.05
Age (year)53.26 ± 5.1153.24 ± 5.2653.20 ± 5.21
Income (¥)>0.05
 <3000252627
 ≥3000353433
Education level>0.05
 High school or below202119
 College or above403941
Drinking282729>0.05
BIM over standard452>0.05

2.2. Inclusion Criteria

The inclusion criteria were as follows: (1) participants and their family members fully understood the research procedures and signed the informed consent. (2) patients of group A were diagnosed with PLC by surgery or biopsy; (3) patients of group B were confirmed with cirrhosis after the examination.

2.3. Exclusion Criteria

Exclusion criteria were as follows: (1) patients with mental illness that prevented normal communication; (2) with other organic diseases; (3) who were in pregnancy or lactation.

2.4. Methods

This study was approved by the ethics committee of The Second Hospital of Dalian Medical University. All the methods were carried out per the Declaration of Helsinki [12]. Detection of serum AFP, TSGF, and GP73 levels: 3 ml of morning fasting venous blood was collected from the patients and centrifuged to obtain the serum. The serum AFP was determined using the electrochemiluminescence method (Cobase 411 electrochemical luminescence device with original auxiliary reagent, Approval No. 3402843 2011), with the range of markers given on the kit as the normal range. The serum TSGF was determined using the colorimetric method (Tai'an City Kangyu Medical Equipment Co. Ltd., Approval No. 2400498). The serum GP73 was determined using the enzyme-linked immunoassay (Beijing Kewei Clinical Diagnostic Reagents Co., Ltd., S20060028). Positive determination of content: serum AFP ≥ 20 ng/mL, TSGF ≥ 70 U/mL, GP73 ≥ 80 ng/mL [13]. MSCT scan: patients were required to lie supine, a 64-row helical CT scanner (Philips, drug safety food machinery into the word no. 3303600 2008) was used for scanning. The scanning parameters were pitch of 1.5, scanning thickness of 0.5 cm, transverse reconstruction thickness of 0.2 cm, current of 160 mA, and voltage of 120 kV. A plain CT scan was performed from the diaphragm to the lower margin of the phalangeal joint. After scanning, 100 mL of iohexol contrast agent was injected at a rate of 2.5–3.0 ml/s, followed by scanning 25 s after injection for the arterial phase and 30 s after injection for the venous phase. The examination results were interpreted independently by two radiologists, and consensus was made after discussion with a third radiologist in the event of discrepancies.

2.5. Observation Criteria

(1) The levels of AFP, TSGF, and GP73 of the participants were analyzed. (2) The diagnostic efficiency of MSCT was analyzed. (3) The diagnostic efficiency of AFP, TSGF, and GP73 was analyzed. (4) The diagnostic efficiency of combined detection was analyzed. Diagnostic efficacy includes (1) sensitivity: the ratio of positive cases in group A to the total in that group. (2) Specificity: the ratio of (number of negative cases in group B + number of negative cases in group C) to (total number of cases in group B + total number of cases in group C). (3) Positive predictive value: the ratio of the number of positive cases in group A to (number of positive cases in groups A, B, and C). (4) Negative predictive value: the ratio of (number of negative cases in group B + number of negative cases in group C) to (number of negative cases in groups A, B, and C).

2.6. Statistical Analysis

SPSS20.0 was used for data analyses, and GraphPad Prism 7 (GraphPad Software, San Diego, USA) was to plot the graphics. The counting data are analyzed using the chi-square test, and the measurement data are analyzed using the t-test. Statistically significant results were defined as P < 0.05.

3. Results

3.1. Analysis of AFP, TSGF, and GP73 Levels

Group A had the highest levels of AFP, TSGF, and GP73, followed by group B, and then group C (P < 0.001), as shown in Figures 1 and 2.
Figure 1

Analysis of AFP and GP73 levels (, μg/L). The horizontal axis from left to right was AFP and GP73, and the vertical axis referred to the level of serum tumor markers (μg/L); the black area in the figure was group A the dark gray indicated group B and the light gray area was for group C. The level of AFP was (142.56 ± 12.10) μg/L in group A, (105.26 ± 10.23) μg/L in group B, and (3.89 ± 0.56) μg/L in group C; the level of GP73 was (156.89 ± 20.56) μg/L in group A, (131.20 ± 12.48) μg/L in group B, and (16.58 ± 4.26) μg/L in group C; P < 0.001.

Figure 2

Analysis of TSGF level (,U/ml). The horizontal axis from left to right was group A group B and group C, respectively, and the vertical axis indicated TSGF level (U/ml). The level of TSGF was (95.56 ± 6.56) U/ml in group A, (54.11 ± 6.26) U/ml in group B, and (39.89 ± 5.48) U/ml in group C; P < 0.001.

3.2. Analysis of Diagnostic Efficiency of Multislice Spiral CT Scanning

The sensitivity, specificity, positive predictive value, and negative predictive value of MSCT were 80.0% (48/60), 91.7% (110/120), 82.8% (48/58), and 90.2% (110/122), respectively, as shown in Table 2.
Table 2

Analysis of diagnostic efficiency of multislice spiral CT scanning.

Multislice CTPathologic examinationTotal
PositiveNegative
Positive481058
Negative12110122
Total60120180

3.3. Diagnostic Efficacy of Serum AFP, TSGF, and GP73

The diagnostic efficiency of serum AFP, TSGF, and GP73 is shown in Table 3.
Table 3

Diagnostic efficacy of serum AFP, TSGF, and GP73.

Sensitivity (%)Specificity (%)Positive predictive value (%)Negative predictive value (%)
AFP66.7 (40/60)70.0 (84/120)52.6 (40/76)80.8 (84/104)
TSGF63.3 (38/60)75.0 (90/120)55.9 (38/68)80.4 (90/112)
GP7383.3 (50/60)81.7 (98/120)69.4 (50/72)90.7 (98/108)

The sensitivity, specificity, positive predictive value and negative predictive value of MSCT combined with serum AFP, TSGF and GP73 were 100.0% (60/60), 93.3% (112/120), 88.2% (60/68) and 100.0% (112/112), respectively.

3.4. Diagnostic Efficacy of Combined Detection

The sensitivity, specificity, positive predictive value, and negative predictive value of multislice spiral CT combined with serum AFP, TSGF, and GP73 were 100.0%, 93.3%, 88.2%, and 100.0%, respectively. The combined detection was associated with significantly a higher detection rate of PLC versus stand-alone detection (P < 0.05), as shown in Table 4.
Table 4

Diagnostic efficiency of combined detection of tumor markers.

Sensitivity (%)Specificity (%)Positive predictive value (%)Negative predictive value (%)
AFP + TSGF70.0 (42/60)75.0 (90/120)58.3 (42/72)83.3 (90/108)
AFP + GP7385.0 (51/60)75.0 (90/120)63.0 (51/81)90.9 (90/99)
GP73 + TSGF83.3 (50/60)78.3 (94/120)65.8 (50/76)90.4 (94/104)
AFP + TSGF + GP7390.0 (54/60)80.0 (96/120)69.2 (54/78)94.1 (96/102)
AFP + TSGF + GP73 + MSCT100.0 (60/60)93.3 (112/120)88.2 (60/68)100.0 (112/112)

4. Discussion

Imaging examination and tumor marker detection are the main methods for PLC diagnosis, but their detection efficiency for small tumors was unsatisfactory [14]. AFP is a serum glycogen protein and its level reaches a peak in the fetal period and declines after delivery. However, injuries and cancerous changes in liver cells can upregulate the expression of AFP [15]. Therefore, the detection of serum AFP levels may contribute to better PLC diagnostic efficiency [16]. However, recent studies found that AFP lacked sensitivity in the diagnosis of early PLC with a high false-positive rate, which compromised its clinical value [17, 18]. In the present study, the sensitivity and specificity of AFP detection for PLC were 66.7% and 70.0%, respectively, which were consistent with the previous research results [19]. TSGF is a polypeptide and exists in the peripheral blood at the early stage of tumor generation [20]. Accordingly, its expression levels in the serum are associated with tumor development. GP73 is a transmembrane glycoprotein that belongs to bile duct epithelial cells in normal tissues [21]. It participates in the inflammatory responses in the body and exerts a great impact on the protein stability of patients [22]. The results of the present study showed that the level of GP73 in patients with PLC was significantly higher than that in healthy people, and the sensitivity of GP73 for PLC was 83.3%, indicating a positive role of GP73 in PLC diagnosis. TSGF is present in the serum of patients with early-stage PLC and can discriminate tumor properties. Both GP73 and AFP are sensitive to PLC, so the combined detection efficiency is superior to that of stand-alone detection. The sensitivity, specificity, positive predictive value, and negative predictive value of TSGF, GP73, and AFP were 90.0 (54/60), 80.0 (96/120), 69.2 (54/78), and 94.1 (96/102), respectively, indicating that the combined detection of tumor markers produced a favorable diagnostic yield. The main blood supply source of healthy liver tissue is the portal vein, while that of PLC patients is the hepatic artery [23]. With blood circulation, the liver cancer lesions of patients gradually disperse, and the diffusion rate of cancer cells rapidly increases through blood metastasis. Multilayer spiral CT scans can clearly visualize the liver lesions of PLC patients [24]. In the present study, contrast-enhanced scanning was performed to compensate for the insufficiency of the original plain scanning, and the sensitivity and specificity of MSCT were 80.0% and 91.7%, respectively, which confirmed the high diagnostic efficiency of MSCT. The sensitivity, specificity, positive predictive value, and negative predictive value of multislice spiral CT combined with serum AFP, TSGF, and GP73 were 100.0%, 93.3%, 88.2%, and 100.0%, respectively. The combined detection was associated with significantly a higher detection rate of PLC versus stand-alone detection (P < 0.05), which was in line with the research results of Poynard T [25]. The sensitivity of multislice spiral CT scan combined with serum AFP, TSGF, and GP73 detection was 98.3% (118/120), proving that the combined detection could increase the early detection rate of PLC. However, this study still has the following deficiencies. First, this study is a single-center study without a blind method, which is prone to researcher bias. Secondly, this study is a cross-sectional diagnostic study, and the relationship between the dynamic changes in the above indicators and the severity and prognosis of primary liver cancer remains unclear. Future studies are to include more cases with long-term follow-up of relevant markers to systematically reflect changes in these markers during disease onset and progression and to provide a more accurate basis for prognosis prediction.

5. Conclusion

MSCT plus serum AFP, TSGF, and GP73 has a higher detection rate versus stand-alone detection, which shows great potential in the diagnosis of PLC.
  25 in total

1.  Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era.

Authors:  Marco Spadaccini; Ana Lleo; Roberto Ceriani; Giovanni Covini; Lorenza Rimassa; Guido Torzilli; Luca Di Tommaso; Alessio Aghemo
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2018-10-28

2.  Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer.

Authors:  Lois A Daamen; Vincent P Groot; Hanne D Heerkens; Martijn P W Intven; Hjalmar C van Santvoort; I Quintus Molenaar
Journal:  HPB (Oxford)       Date:  2018-02-01       Impact factor: 3.647

3.  Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT.

Authors:  Wei Guo; Yizhen Pang; Lanlin Yao; Liang Zhao; Chunlei Fan; Jingpeng Ke; Ping Guo; Bing Hao; Hao Fu; Chengrong Xie; Qin Lin; Hua Wu; Long Sun; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-11       Impact factor: 9.236

4.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

5.  Liquid biopsy and multiparametric analysis in management of liver malignancies: new concepts of the patient stratification and prognostic approach.

Authors:  Olga Golubnitschaja; Jiri Polivka; Kristina Yeghiazaryan; Leonard Berliner
Journal:  EPMA J       Date:  2018-08-17       Impact factor: 6.543

6.  A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy.

Authors:  Suguru Hirose; Kazunori Ishige; Masamichi Yamaura; Tsuneo Mizui; Yoshiki Komatsu; Masaomi Nagase; Masashi Sato; Junji Hattori; Masato Endo; Naoyuki Hasegawa; Kuniaki Fukuda; Ichinosuke Hyodo
Journal:  Clin J Gastroenterol       Date:  2020-06-15

Review 7.  Radiomics in hepatocellular carcinoma: a quantitative review.

Authors:  Taiga Wakabayashi; Farid Ouhmich; Cristians Gonzalez-Cabrera; Emanuele Felli; Antonio Saviano; Vincent Agnus; Peter Savadjiev; Thomas F Baumert; Patrick Pessaux; Jacques Marescaux; Benoit Gallix
Journal:  Hepatol Int       Date:  2019-08-31       Impact factor: 9.029

8.  Prevalence of Chronic Hepatitis B and C Infection in Mongolian Immigrants in the Washington, District of Columbia, Metropolitan Area, 2016-2017.

Authors:  Emmeline Ha; Frederic Kim; Janice Blanchard; Hee-Soon Juon
Journal:  Prev Chronic Dis       Date:  2019-01-24       Impact factor: 2.830

Review 9.  Radiomics and radiogenomics of primary liver cancers.

Authors:  Woo Kyoung Jeong; Neema Jamshidi; Ely Richard Felker; Steven Satish Raman; David Shinkuo Lu
Journal:  Clin Mol Hepatol       Date:  2018-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.